Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus

Cited by (452)

Items 201–300 of 452

1. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes
   Vincent C. Woo · 2019 · Canadian Journal of Diabetes
2. A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
   Junichi Mukai, Shinya Kanno, Rie Kubota · 2021 · Scientific Reports
3. Effect of Quercetin Supplement on Some Bone Mineralization Biomarkers in Diabetic Type 2 Patients
   Jubran K. Hassan, Adheed Khalid Sharrad, Falah H. Sheri · 2018 · Advances in Pharmacology and Pharmacy
4. Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, Improves Trabecular Bone Mineral Density and Microstructure in Obese, Insulin-Resistant, Pre-diabetic Rats
   Narattaphol Charoenphandhu, Panan Suntornsaratoon, Piangkwan Sa‐nguanmoo, Pongpan Tanajak, Jarinthorn Teerapornpuntakit, Ratchaneevan Aeimlapa, Nipon Chattipakorn, Siriporn Chaisin Chattipakorn · 2018 · Canadian Journal of Diabetes
5. Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin
   Sarfaraz Alam Khan, Mubashar Sultan Hashmi, Muhammad Asim Rana, Ghulam Mujtaba Zafar, Sadia Asif, Muhammad Talha Farooq, Sarmad Zahoor · 2022 · Cureus
6. SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake
   Wafaa N. Albalawy, Elynna B. Youm, Katherine E. Shipman, Keelan J. Trull, Catherine J. Baty, Kimberly R. Long, Youssef Rbaibi, Xue‐Ping Wang, Olayemi G. Fagunloye, Katharine A. White et al. · 2024 · American Journal of Physiology-Renal Physiology
7. Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
   John E. Anderson, Eugene E. Wright, Charles F. Shaefer · 2016 · Diabetes Therapy
8. Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone
   Kathryn M. Thrailkill, R. Clay Bunn, Sasidhar Uppuganti, Philip D. Ray, Kate Garrett, Iuliana Ristea Popescu, Jacquelyn S. Pennings, John L. Fowlkes, Jeffry Stephen Nyman · 2020 · Bone
9. Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?
   Edoardo Mannucci, Matteo Monami · 2016 · Drug Safety
10. Diabetes management before, during, and after bariatric and metabolic surgery
    Karim G. Kheniser, Sangeeta Rao Kashyap · 2018 · Journal of Diabetes and its Complications
11. SGLT2 Inhibitors—Sweet Success for Diabetic Kidney Disease?
    Ian H. de Boer, Steven E. Kahn · 2016 · Journal of the American Society of Nephrology
12. A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
    David Aristizábal-Colorado, David Corredor-Rengifo, Santiago Sierra-Castillo, Carolina López-Corredor, David Alexander Vernaza Trujillo, Danilo Weir-Restrepo, Juan S. Izquierdo‐Condoy, Esteban Ortiz‐Prado, Jorge E. Rico-Fontalvo, Juan‐Esteban Gomez‐Mesa et al. · 2025 · Frontiers in Endocrinology
13. Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits
    Kathryn M. Thrailkill, R. Clay Bunn, Sasidhar Uppuganti, Philip D. Ray, Iuliana Ristea Popescu, Evangelia Kalaitzoglou, John L. Fowlkes, Jeffry Stephen Nyman · 2020 · Bone
14. Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study
    Bin Zhao, Juan Shen, Jun Zhao, Hui Pan · 2020 · Journal of Diabetes Investigation
15. Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real‐world clinical practice in Korea: A national observational cohort study
    Kyoung Hwa Ha, Dae Jung Kim, Yong Jun Choi · 2022 · Journal of Diabetes Investigation
16. Management of fracture risk in patients with diabetes—Chinese Expert Consensus
    Jianmin Liu, Dalong Zhu, Yiming Mu, Weibo Xia · 2019 · Journal of Diabetes
17. Glucose-Lowering Drugs and Fracture Risk—a Systematic Review
    Zheer Kejlberg Al-Mashhadi, Rikke Viggers, Rasmus Fuglsang-Nielsen, Frank de Vries, Joop P. van den Bergh, Torben Harsløf, Bente Lomholt Langdahl, Søren Gregersen, Jakob Starup‐Linde · 2020 · Current Osteoporosis Reports
18. Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel
    Iacopo Chiodini, Agostino Gaudio, Andrea Palermo, Nicola Napoli, Fabio Vescini, Alberto Falchetti, Daniela Merlotti, Cristina Eller-Vainicher, Vincenzo Carnevale, Alfredo Scillitani et al. · 2021 · Nutrition Metabolism and Cardiovascular Diseases
19. SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
    Elamin Abdelgadir, Fouzia Rashid, Alaaeldin M. Bashier, Razan Ali · 2018 · Journal of Clinical Medicine Research
20. SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
    Matthew C. Riddle, William T. Cefalu · 2018 · Diabetes Care
21. The interplay between bone and heart health as reflected in medication effects: A narrative review
    Susanne Ursula Trost, Nolawit Tesfaye, Tasma Harindhanavudhi · 2023 · Women s Health
22. Mechanism of traditional Chinese medicine in elderly diabetes mellitus and a systematic review of its clinical application
    Qiqi Zhang, Shiwan Hu, Zishan Jin, Sicheng Wang, Boxun Zhang, Linhua Zhao · 2024 · Frontiers in Pharmacology
23. Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality
    Monika Martiniaková, Vladimíra Mondočková, Veronika Kováčová, Martina Babikova, Nina Zemanová, Roman Bíro, Noémi Pénzes, Radoslav Omelka · 2024 · Diabetology & Metabolic Syndrome
24. Practical considerations for the use of sodium–glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes
    Karen S.L. Lam, Chun Chung Chow, K. C. B. Tan, Ronald C.W., Alice P.S. Kong, Peter C.Y. Tong, Man Wo Tsang, Tak Mao Chan, Sydney C.W. Tang, Ka Kui Lee et al. · 2016 · Current Medical Research and Opinion
25. Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients
    Nobuya Inagaki, Shin‐ichi Harashima, Hiroaki Iijima · 2018 · Expert Opinion on Pharmacotherapy
26. Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence
    Leonardo Pozo, Fatimah Oluwakemi Bello, Andrés Suárez, Francisco E. Ochoa-Martinez, Yamely H. Mendez, Chelsea Chang, Salim Surani · 2019 · World Journal of Diabetes
27. SGLT-2 Inhibitors and DPP-4 Inhibitors as Second-Line Drugs in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials
    Keke Wang, Yansong Zhang, Chunyang Zhao, Mingyan Jiang · 2018 · Hormone and Metabolic Research
28. Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update
    Fernando Gómez Peralta, Francisco Javier Escalada San Martín, Edelmiro Luis Menéndez Torre, Manel Mata‐Cases, Juan Carlos Ferrer García, Patxi Ezkurra Loiola, Luis Ávila Lachica, José Antonio Fornos Pérez, Sara Artola Menéndez, Fernando Álvarez Guisasola et al. · 2018 · Endocrinología Diabetes y Nutrición (English ed )
29. Double‐blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: A pilot study
    Sangeeta Rao Kashyap, Karim G. Kheniser, Ali Aminian, Philip R. Schauer, Carel Wynand le Roux, Bartolome G. Burguera · 2020 · Obesity Science & Practice
30. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus
    Nishant Garodia, K.M. PRASANNA KUMAR, Sujoy Ghosh, William J. Canovatchel, Sujith Tumkur Rajashekar · 2016 · Indian Journal of Endocrinology and Metabolism
31. New Glucose-Lowering Agents for Diabetic Kidney Disease
    Lisanne C. de Vos, Thushan Hettige, Mark Emmanuel Cooper · 2018 · Advances in Chronic Kidney Disease
32. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials
    Atsunori Kashiwagi, Marina Vladimirovna Shestakova, Yuichiro Ito, Masahiro Noguchi, Wim Wilpshaar, Satoshi Yoshida, John P.H. Wilding · 2019 · Diabetes Therapy
33. Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes
    Nithya J Gogtay, Debdipta Bose, Urmila M Thatte · 2018 · New England Journal of Medicine
34. Bone Metabolism and Fracture Risk in Diabetes Mellitus
    Melisa Puspitasari, Dyah Purnamasari, Bambang Setyohadi, Harry Isbagio · 2017 · Journal of the ASEAN Federation of Endocrine Societies
35. Natural and chemical compounds as protective agents against cardiac lipotoxicity
    Fatemeh Yarmohammadi, Andrew Wallace Hayes, Gholamreza Karimi · 2021 · Biomedicine & Pharmacotherapy
36. Treatment of Diabetes and Osteoporosis—A Reciprocal Risk?
    Agnieszka Ewa Zawada, Alicja Ewa Ratajczak, Anna Maria Rychter, Aleksandra Szymczak‐Tomczak, Agnieszka Dobrowolska, Iwona Krela‐Kaźmierczak · 2022 · Biomedicines
37. Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies
    Mohamed E. A. Mostafa, Tariq Alrasheed · 2024 · Frontiers in Endocrinology
38. Clinical aspects and management of osteoporosis and fragility fractures in patients with diabetes
    Manju Chandran · 2017 · Osteoporosis and Sarcopenia
39. Effects of Sodium–Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction
    Salva R. Yurista, Herman H.W. Silljé, Harry van Goor, Jan‐Luuk Hillebrands, Hiddo J.L. Heerspink, Luiz de Menezes Montenegro, Silke U. Oberdorf‐Maass, Rudolf A. de Boer, Berend Daan Westenbrink · 2020 · Cardiovascular Drugs and Therapy
40. Effects of 1‐year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes
    Ikuro Matsuba, Masahiro Takihata, Masahiko Takai, Hajime Maeda, Akira Kubota, Kotaro Iemitsu, Shinichi Umezawa, Mitsuo Obana, Mizuki Kaneshiro, Takehiro Kawata et al. · 2021 · Diabetes Obesity and Metabolism
41. Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
    Jeonghoon Ha, Yejee Lim, Mee Kyoung Kim, Hyuk‐Sang Kwon, Ki‐Ho Song, Seung‐Hyun Ko, Moo Il Kang, Sung Dae Moon, Ki‐Hyun Baek · 2021 · Endocrinology and Metabolism
42. The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
    Kalliopi Pafili, Efstratios S. Maltezos, Νικόλαος Παπάνας · 2016 · Expert Opinion on Investigational Drugs
43. Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: A population-based cohort study
    Judith de Ruijter-van Dalem, Nikki C. C. Werkman, Joop P. van den Bergh, Bernardette Rossi, Rikke Viggers, Richard Eastell, Andrea Michelle Burden, Coen D.A. Stehouwer, Olaf H. Klungel, Martijn C.G.J. Brouwers et al. · 2022 · Diabetes Research and Clinical Practice
44. Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?
    Angelika Bielach-Bazyluk, Jolanta Małyszko, Edyta Zbroch · 2018 · Postgraduate Medicine
45. Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice
    Claire Gerber, Xueyan Wang, Valentin David, Susan E. Quaggin, Tamara Isakova, Aline Martin · 2021 · JBMR Plus
46. Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
    Annamaria Mascolo, Concetta Rafaniello, Gabriella di Mauro, Donatella Ruggiero, Maria Rosaria Campitiello, Maria Donniacuo, Pasquale Maria Berrino, Francesco Rossi, Giuseppe Paolisso, Annalisa Capuano · 2023 · Frontiers in Pharmacology
47. SGLT2 inhibitors use in kidney disease: what did we learn?
    Munaza Akunjee, Shikha Khosla, Eric Sixtus Nylen, Sabyasachi Sen · 2025 · American Journal of Physiology-Endocrinology and Metabolism
48. SGLT2 inhibitors
    Erika Opingari, Arun C.R. Partridge, Subodh Verma, HARPREET SINGH BAJAJ · 2018 · Current Opinion in Cardiology
49. Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: A network meta-analysis
    Wen-Hsuan Tsai, Siang-Ke Kong, Chu-Lin Lin, Kai-Hsuan Cheng, Yi-Ting Cheng, Ming-Nan Chien, Chun‐Chuan Lee, Ming-Chieh Tsai · 2022 · Diabetes Research and Clinical Practice
50. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)
    Masaya Koshizaka, Ko Ishikawa, Takahiro Ishikawa, Kazuki Kobayashi, Minoru Takemoto, Takuro Horikoshi, Ryota Shimofusa, Sho Takahashi, Kengo Nagashima, Yasunori Sato et al. · 2017 · BMJ Open
51. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
    Amr Dokmak, Mohammad Almeqdadi, Hirsh D. Trivedi, Sandeep Krishnan · 2019 · World Journal of Hepatology
52. Diabetes mellitus and osteoporosis
    Stavroula Α. Paschou, Andromachi Vryonidou · 2020 · Minerva Endocrinology
53. Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice
    Gozde Yildirim, Edmara T. P. Bergamo, Sher Bahadur Poudel, Ryan Richard Ruff, Manisha Dixit, Bin Hu, Dindo Q. Mijares, Lukasz Witek, Carolyn Chlebek, David E. Harrison et al. · 2023 · GeroScience
54. Diabetes and Osteoporosis
    Trupti Nagendra Prasad, Durairaj Arjunan, Rimesh Pal, Sanjay Kumar Bhadada · 2023 · Indian Journal of Orthopaedics
55. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology
    Jyoti Yadav, Farogh Ahsan, Prabhudatta Panda, Tarique Mahmood, Valeed Ahmad Ansari, Arshiya Shamim · 2024 · Current Diabetes Reviews
56. Association of sodium-glucose cotransporter 2 inhibitor use with risk of osteoporotic fracture among older women: A nationwide, population-based cohort study
    Seunghyun Lee, Min Heui Yu, Namki Hong, Kyoung Jin Kim, Hae Kyung Kim, Yumie Rhee, Minyoung Lee, Kyoung Min Kim · 2024 · Diabetes Research and Clinical Practice
57. The Effects of Diabetes and Diabetic Medications on Bone Health
    Yasmine M. Elamir, Arianna L. Gianakos, Joseph M. Lane, Anupa Sharma, William Grist, Frank A. Liporace, Richard S. Yoon · 2019 · Journal of Orthopaedic Trauma
58. Effect of Antidiabetic Drugs on Bone Health in Patients with Normal Renal Function and in Chronic Kidney Disease (CKD): Insight into Clinical Challenges in the Treatment of Type 2 Diabetes
    Cristiana Cipriani, Gabriella Lauriero, Giovanni Luigi Tripepi, Serge Ferrari, Jordi Bover, Maura Ravera, Simona Barbuto, Giuseppe Cianciolo, Luca De Nicola, Maria Luisa Brandi et al. · 2023 · Journal of Clinical Medicine
59. Weak bones in diabetes mellitus – an update on pharmaceutical treatment options
    Daphne Lin, Crispin R. Dass · 2017 · Journal of Pharmacy and Pharmacology
60. Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
    Alice L Bhasale, Barbara J. Mintzes, Ameet Sarpatwari · 2020 · BMJ
61. Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
    Eddison Godinez Leiva, Fernando Bril · 2020 · Current Hypertension Reviews
62. Diabetic bone fragility through advanced glycation end product-collagen axis: Mechanisms and therapy of sodium glucose cotransporter 2 inhibitors
    Zhi-Peng Li, Cheng Luo, Xue Fei Yu, Liya Ye, Da Sun, Chen Duan, Shiyu Xu, Mei-Qi Zeng, Hui Xu, Zi-Yuan Peng et al. · 2025 · World Journal of Diabetes
63. Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes
    Rong Qiu, Dainius A. Balis, George A. Capuano, John Xie, Gary E. Meininger · 2016 · Diabetes Therapy
64. Cardiovascular outcome trials of diabetes drugs: lessons learned
    Simeon I. Taylor, Bruce R. Leslie · 2018 · Journal of Clinical Investigation
65. Disorders of water and sodium homeostasis and bone
    Rachel L. Usala, Joseph George Verbalis · 2018 · Current Opinion in Endocrine and Metabolic Research
66. Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
    Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Stavroula Α. Paschou, Evangelos K. Oikonomou, Vasiliki Tsigkou, Alexios S. Antonopoulos, Manolis Vavuranakis, Dimitrios M. Tousoulis · 2020 · Current Pharmaceutical Design
67. Chinese Guidelines for Medical Nutrition Therapy for Patients with Diabetes (2022 Edition).
    2024 · PubMed Central
68. Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations
    Muthanna K. Zaki, Mohammed Najim Abed, Fawaz Abdulghani Alassaf · 2024 · Journal of Bone Metabolism
69. Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials’ meta-analysis studies
    Pouria Khashayar, Farid Farahani Rad, Ozra Tabatabaei‐Malazy, Sara MohammadHosseinzadeh Golabchi, Patricia Khashayar, Mehdi Mohammadi, Sholeh Ebrahimpour, Bagher A. Larijani · 2024 · Diabetology & Metabolic Syndrome
70. Mechanistic underpinnings of AGEs-RAGE via DIAPH1 in ischemic, diabetic, and failing hearts
    Gautham Yepuri, Syed Nurul Hasan, Vikas S. Kumar, Michaele B. Manigrasso, Gregory G. Theophall, Alexander G. Shekhtman, Ann Marie Schmidt, Ravichandran Ramasamy · 2025 · American Journal of Physiology-Heart and Circulatory Physiology
71. Different Forms of Regulated Cell Death in Type-2-Diabetes-Mellitus-Related Osteoporosis: A Focus on Mechanisms and Therapeutic Strategies
    Chenchen Li, He Gong, Peipei Shi, Shuyu Liu, Qi Zhang · 2025 · International Journal of Molecular Sciences
72. Is there a relationship between gliflozins and acute pancreatitis? Evidence-based analysis
    Marina Stopa Couto, Marcelo Adrián Estrín · 2022 · Data & Metadata
73. Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens
    Sharon Wu Lahiri · 2017 · Clinical Diabetes
74. Thyroid Hormones, Glucocorticoids, Insulin, and Bone
    Peter L. Lakatos, Balázs Szili, Bence Bakos, István Takács, Zsuzsanna Putz, Ildikó Istenes · 2019 · Handbook of experimental pharmacology
75. Update on: effects of anti-diabetic drugs on bone metabolism
    Guillaume Mabilleau, Béatrice Bouvard · 2020 · Expert Review of Endocrinology & Metabolism
76. Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
    Giulia Ferrannini, Norman R Rosenthal, Michael K. Hansen, Ele Ferrannini · 2022 · Cardiovascular Diabetology
77. Cardiovascular safety of therapies for type 2 diabetes
    Puneet Kumar Gupta, William B. White · 2016 · Expert Opinion on Drug Safety
78. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT)
    Ai Haraguchi, Riyoko Shigeno, Ichiro Horie, Shimpei Morimoto, Ayako Ito, Ko Chiba, Yurika Kawazoe, Shigeki Tashiro, Junya Miyamoto, Shuntaro Sato et al. · 2020 · Trials
79. Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
    Guntram Schernthaner, Sarah Jarvis, Chaim Lotan, Martin Prázný, Christoph Wanner, Thomas C. Wascher · 2017 · Therapeutics and Clinical Risk Management
80. The effect of antidiabetic drugs on bone metabolism: a concise review
    Stavroula Psachna, Maria Eleni Chondrogianni, Konstantinos D. Stathopoulos, Antonis Polymeris, Antonios Chatzigeorgiou, Efstathios Chronopoulos, Symeon Tournis, Eva N. Kassi · 2024 · Endocrine
81. Effect of a Multifactorial Intervention on Fracture in Patients With Type 2 Diabetes: Subanalysis of the J-DOIT3 Study
    Takayoshi Sasako, Kohjiro Ueki, Kana Miyake, Yukiko Okazaki, Yasuhiro Takeuchi, Yasuo Ohashi, Mitsuhiko Noda, Takashi Kadowaki · 2021 · The Journal of Clinical Endocrinology & Metabolism
82. Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
    Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae‐Hyoung Cho, In‐Kyung Jeong, Soon Hee Lee, Ji‐Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho et al. · 2022 · Diabetes & Metabolism Journal
83. A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures
    Charmi A. Patel, Robert A. Bailey, Ujjwala Vijapurkar, Gary E. Meininger, Lawrence Blonde · 2016 · BMC Health Services Research
84. Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm
    Azza Khalifa Bin Hussain, Elamin Abdelgadir, Fouzia Rashid, Abeer Alhaj, Puja Thadani, Alaaeldin M. Bashier · 2019 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
85. Comparison of FRAX in postmenopausal Asian women with and without type 2 diabetes mellitus: a retrospective observational study
    Chen Wang, Jun Liu, Li Xiao, Dan Liu, Wenjing Yan, Ting Hu, Kunhong Li, Xiaociao Hua, Xianshang Zeng · 2019 · Journal of International Medical Research
86. An evaluation of canagliflozin for the treatment of type 2 diabetes: an update
    Taichi Minami, Akiko Kameda, Yasuo Terauchi · 2021 · Expert Opinion on Pharmacotherapy
87. Prevalence of Osteoporosis in Type 2 Diabetes Mellitus Patients Using Dual Energy X-Ray Absorptiometry (DEXA) Scan
    Shivank Prakash, Ravi S Jatti, Shridhar C. Ghagane, Sujatha M Jali, Mallikarjun V. Jali · 2017 · International Journal of Osteoporosis and Metabolic Disorders
88. Fractures in women with type 2 diabetes are associated with marked deficits in cortical parameters and trabecular plates
    Sanchita Agarwal, Carmen Germosen, Isabella Rosillo, Mariana Bucovsky, Ivelisse Colón, Nayoung Kil, Zexi Wang, A. Teodora Dinescu, Xiang-Dong Edward Guo, Marcella Donovan Walker · 2024 · Journal of Bone and Mineral Research
89. Medication-induced fractures: Screening and treatment strategies
    Laraib Javed, Aemen Shams Khakwani, Uzair Khan, Mary Beth Humphrey · 2024 · The American Journal of the Medical Sciences
90. The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus
    Veerle van Hulten, Johanna H. M. Driessen, Jakob Starup‐Linde, Zheer Kejlberg Al-Mashhadi, Rikke Viggers, Olaf H. Klungel, Patrick Cyriel Souverein, Peter Vestergaard, Coen D.A. Stehouwer, Joop P. van den Bergh · 2023 · Diabetes Obesity and Metabolism
91. Evaluation of the safety of sodium‐glucose co‐transporter‐2 inhibitors for treating patients with type 1 diabetes
    Weihao Wang, Lina Zhang, Xiaobei Pei, Qi Pan, Lixin Guo · 2020 · Diabetes Obesity and Metabolism
92. Oral antidiabetic agents: Recently available novel oral antidiabetic agents in India: A clinical review
    Nitin Kapoor, Nihal Thomas · 2017 · Current Medical Issues
93. Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
    Ying Hu · 2019 · Chronic Diseases and Translational Medicine
94. Paris polyphylla Sm. extract enriched with diosgenin as an antidiabetic agent: In vitro and in vivo study
    Vimi Kshetrimayum, Khaidem Devika Chanu, Suparna Ghosh, Pallab Kanti Haldar, Pulok Kumar Mukherjee, Nanaocha Sharma · 2023 · Phytomedicine Plus
95. Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
    Jaime Sanz‐Cánovas, Michele Ricci, Lidia Cobos-Palacios, Almudena López Sampalo, Halbert Hernández-Negrín, María Vázquez-Márquez, Juan José Mancebo-Sevilla, Elena Álvarez-Recio, Maria Dolores Lopez-Carmona, Miguel Ángel Pérez Velasco et al. · 2023 · Reviews in Cardiovascular Medicine
96. The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
    Teodor Salmen, Florin Teodor BOBIRCA, Ioana-Cristina Bica, Doina Andrada Mihai, Corina Silvia Pop, Anca Pantea Stoian · 2023 · Life
97. Association between site‐specific bone mineral density and glucose homeostasis and anthropometric traits in healthy men and women
    Se‐Min Kim, Jinrui Cui, Jane Rhyu, Xiuqing Guo, Yii‐Der Ida Chen, Willa A. Hsueh, Jerome I. Rotter, Mark O. Goodarzi · 2018 · Clinical Endocrinology
98. Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD
    Alexander J. Kula · 2022 · Pediatric Nephrology
99. Pharmacovigilance in the Real World
    William Donald Leslie, John T. Schousboe · 2018 · Annals of Internal Medicine
100. Managing Bone Fragility in Older Adults with Diabetes: Pathophysiology, Assessment, and Therapeutic Considerations
     Gülistan Bahat, T. Obekli Erdogan, Savaş Öztürk, Özlem Soyluk Selçukbiricik, Serdar Özkök, Dilek Gogas Yavuz, M.A. Karan, Jean‐Yves Reginster · 2026 · Drugs & Aging